JP2012515210A - ベンダムスチン遊離塩基の新規の形態 - Google Patents

ベンダムスチン遊離塩基の新規の形態 Download PDF

Info

Publication number
JP2012515210A
JP2012515210A JP2011546322A JP2011546322A JP2012515210A JP 2012515210 A JP2012515210 A JP 2012515210A JP 2011546322 A JP2011546322 A JP 2011546322A JP 2011546322 A JP2011546322 A JP 2011546322A JP 2012515210 A JP2012515210 A JP 2012515210A
Authority
JP
Japan
Prior art keywords
free base
bendamustine free
bendamustine
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515210A5 (enExample
Inventor
コルボアジェ、ローレント、ディー．
エドレストン、マーク
ハルティワンガー、カーティス、アール．
マッキーン、ロバート、イー．
Original Assignee
セファロン、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012515210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セファロン、インク． filed Critical セファロン、インク．
Publication of JP2012515210A publication Critical patent/JP2012515210A/ja
Publication of JP2012515210A5 publication Critical patent/JP2012515210A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP2011546322A 2009-01-15 2010-01-14 ベンダムスチン遊離塩基の新規の形態 Pending JP2012515210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
US61/144,843 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (2)

Publication Number Publication Date
JP2012515210A true JP2012515210A (ja) 2012-07-05
JP2012515210A5 JP2012515210A5 (enExample) 2013-02-28

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546322A Pending JP2012515210A (ja) 2009-01-15 2010-01-14 ベンダムスチン遊離塩基の新規の形態

Country Status (16)

Country Link
US (1) US8076366B2 (enExample)
EP (1) EP2387400A1 (enExample)
JP (1) JP2012515210A (enExample)
KR (1) KR20110110293A (enExample)
CN (2) CN103554030A (enExample)
AU (2) AU2010204765A1 (enExample)
BR (1) BRPI1004922A2 (enExample)
CA (1) CA2749101A1 (enExample)
EA (1) EA020767B1 (enExample)
IL (1) IL213725A0 (enExample)
MX (1) MX2011007557A (enExample)
NZ (1) NZ594010A (enExample)
SG (1) SG172810A1 (enExample)
UA (1) UA109109C2 (enExample)
WO (1) WO2010083276A1 (enExample)
ZA (1) ZA201105099B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512529A (ja) * 2013-03-12 2016-04-28 セファロン、インク． ナノ粒子及びナノ粒子製剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376394B2 (en) * 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2720547A4 (en) * 2011-06-20 2014-11-05 Hetero Research Foundation PROCESS FOR BENDAMUSTINE HYDROCHLORIDE
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
WO2014176070A1 (en) 2013-04-26 2014-10-30 Vital Art & Science Incorporated Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (enExample)
DE159877C (enExample)
DE293808C (enExample)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
JP2002520282A (ja) 1998-07-09 2002-07-09 フランシス エイ． ナーデラ， 慢性リンパ性白血病の処置のための方法および組成物
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025881A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
DK1435877T3 (da) 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
AU2003221517B2 (en) 2002-03-22 2010-02-18 Christian Straka Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1501565B1 (de) 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
US20040096436A1 (en) 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
MX2011003751A (es) * 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512529A (ja) * 2013-03-12 2016-04-28 セファロン、インク． ナノ粒子及びナノ粒子製剤

Also Published As

Publication number Publication date
CN103554030A (zh) 2014-02-05
AU2016204902A1 (en) 2016-08-04
CN102281877B (zh) 2014-07-23
KR20110110293A (ko) 2011-10-06
UA109109C2 (uk) 2015-07-27
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
CA2749101A1 (en) 2010-07-22
ZA201105099B (en) 2012-03-28
MX2011007557A (es) 2011-08-12
EP2387400A1 (en) 2011-11-23
US8076366B2 (en) 2011-12-13
BRPI1004922A2 (pt) 2019-09-24
NZ594010A (en) 2013-08-30
SG172810A1 (en) 2011-08-29
CN102281877A (zh) 2011-12-14
US20100210701A1 (en) 2010-08-19
AU2010204765A1 (en) 2011-07-28
IL213725A0 (en) 2011-07-31
WO2010083276A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
US8076366B2 (en) Forms of bendamustine free base
HK1220966A1 (zh) 盐酸苯达莫司汀固体形式
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
CN121889396A (zh) 用于治疗甲状腺眼病的林西替尼的结晶盐
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
US20250136610A1 (en) Crystalline forms of trilaciclib and trilaciclib salts
AU2017342239B2 (en) Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-N-methylpicolinamide
US12012421B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP4512808A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
KR20230026384A (ko) 화합물의 결정 형태
US20240409501A1 (en) Cyrstalline forms of rip1 inhibitor
CN101228151B (zh) 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐
WO2026067446A1 (zh) 一种大稠环化合物的盐、多晶型物及其应用
WO2017029408A1 (en) Solid state forms of sofosbuvir
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt
CN112142730A (zh) 杂芳基并四氢吡啶类化合物的固体形式及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141216